### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Toren Finkel et al.

Application No.: To be assigned

Filed: To be assigned

Confirmation No.: To be assigned

For: METHOD FOR DIAGNOSIS AND

TREATMENT OF VASCULAR DISEASE

Examiner: To be assigned Art Unit: To be assigned

Attorney Reference No. 4239-67020-02

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

#### CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV510808780US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)

Date Mailed May 11, 2005

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Ву

Susan Alpert Siegel, PhD. Registration No. 43,121

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

E-037-2003/1-US-02

EXPEMAIL LABEL NO.: EV510808780US

JC14 mec'd PCT/PYO 11 MAY 2005

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67020-02
Application Number	To be assigned
Filing Date	To be assigned
First Named Inventor	Toren Finkel
Art Unit	To be assigned
Examiner Name	To be assigned

### U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	<b>Publication Date</b>	Name of Applicant or Patentee
		4,403,041	06 Sept 1983	Bürk et al.
		6,156,500	05 Dec 2000	Falb
	:			

## FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee		
Examiner's	Cite No.						
Initials*	(optional)	OTHER DOCUMENTS					
		Asahara et al., Science 275:964-967, 1997					
		Asahara et al., Circulation Research 85:221-228, 1999					
		Asahara et al., The EMBO Journal 18(14):3964-3972, 1999					
		Bahlmann et al., <i>Blood</i> 103(3):921-926, 2004					
		Dimmeler et al., The Journal of Clinical Investigation 108(3):391-397, 2001					
		Eizawa et al., Current Medical Research and Opinion 19(7):627-633, 2003					
		Gokce et al., Circulation 105:1567-1572, 2002					
		Grant et al., Nature Medicine 8(6):607-612, 2002					

EXAMINER DATE SIGNATURE: CONS	SIDERED:

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

39 E-037-2003/1-US-02

MAIL LABEL NO.: EV510808780US

			JCT Rec'd PCT	/PTO 11 MAY 2005
			Attorney Docket Number	4239-67020-02
			Application Number	To be assigned
INFOR	MATION	N DISCLOSURE STATEMENT	Filing Date	To be assigned
BY APPLICANT			First Named Inventor	Toren Finkel
			Art Unit	To be assigned
			Examiner Name	To be assigned
xaminer's Initials*	Cite No. (optional)	OTHER DOCUMENTS		
		Halcox et al., Circulation 106:653-6	falcox et al., Circulation 106:653-658, 2002	
Hill et al. The New England Journal of Medicine 348(7):593-600, 2003		2003		

			Examiner Name	To be assigned			
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS					
		Halcox et al., Circulation 106:653-6	58, 2002				
		Hill et al., The New England Journal of Medicine 348(7):593-600, 2003					
Kalka et al., Circulation Research 86:1198-1202, 200		5:1198-1202, 2000					
	Kocher et al., Nature Medicine 7(4):430-436, 2001						
		Llevadot et al., The Journal of Clinic	cal Investigation 108(3):399	9-405, 2001			
		Luttun et al., Trends Cardiovasc Med	d 12(2):88-96, 2002				
· <del></del>		Murohara et al., The Journal of Clina	ical Investigation 105(11):1	527-1536, 2000			
		Perticone et al., Circulation 104:191	-196, 2001	<u> </u>			
		Powell et al., Arterioscler Thromb V	asc Biol. 25:296-301, 2005				
		Schächinger et al., Circulation 101:1	899-1906, 2000				
	_	Seiler et al., Circulation 104:2012-20	017, 2001				
		Shintani et al., Circulation 103:2776	-2779, 2001				
		Suwaidi et al., Circulation 101:948-9	954, 2000				
		Vasa et al., Circulation Research. 89	:e1-e7, 2001				
		Vasa et al., Circulation 103:2885-28	90, 2001				

EXAMINER	DATE
SIGNATURE:	CONSIDERED:
	L

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.